U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H34AuO9PS
Molecular Weight 678.4858
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AURANOFIN

SMILES

CC(=O)OC[C@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.CCP(CC)CC.[Au+]

InChI

InChIKey=IRPYFWIZKIOHQN-XTZHGVARSA-N
InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/t10-,11-,12+,13-,14+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C20H36AuO9PS
Molecular Weight 680.5016
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Auranofin (brand name Ridaura) is an organogold compound classified by the World Health Organization as an antirheumatic agent. Ridaura is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. The mechanism of action of is not understood. In patients with adult rheumatoid arthritis, it may modify disease activity as manifested by synovitis and associated symptoms, and reflected by laboratory parameters such as ESR. There is no substantial evidence, however, that gold-containing compounds induce remission of rheumatoid arthritis. It may act as an inhibitor of kappab kinase and thioredoxin reductase, which would lead to a decreased immune response and decreased free radical production, respectively. In patients with inflammatory arthritis, such as adult and juvenile rheumatoid arthritis, gold salts can decrease the inflammation of the joint lining. This effect can prevent destruction of bone and cartilage. Ridaura should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P30044|||Q9UJU4
Gene ID: 25824.0
Gene Symbol: PRDX5
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
RIDAURA

Approved Use

RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months. When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage. In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy.

Launch Date

4.85740806E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.312 μg/mL
6 mg 1 times / day multiple, oral
dose: 6 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AURANOFIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5.05 μg × h/mL
6 mg 1 times / day multiple, oral
dose: 6 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AURANOFIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
844 h
6 mg 1 times / day multiple, oral
dose: 6 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AURANOFIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.1310
unhealthy, 22-76
n = 72
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 22-76
Sex: M+F
Population Size: 72
Sources: Page: p.1310
Disc. AE: Stomatitis, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Stomatitis (1.4%)
Diarrhea (1.4%)
Eosinophilia (1.4%)
Leukopenia (1.4%)
Sources: Page: p.1310
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.2
healthy, 27+/-5
n = 15
Health Status: healthy
Age Group: 27+/-5
Sex: M+F
Population Size: 15
Sources: Page: p.2
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Disc. AE: Exanthema, Pruritus...
AEs leading to
discontinuation/dose reduction:
Exanthema (7.5%)
Pruritus (6%)
Diarrhea (3%)
Nausea (1.5%)
Bowel obstruction (1.5%)
Glomerulonephritis (1.5%)
Nephropathies (1.5%)
Polyneuropathy (1.5%)
Sweating (1.5%)
Dry mouth (1.5%)
Sources: Page: p.254
27 mg 1 times / day multiple, oral (total daily dose)
Overdose
Dose: 27 mg, 1 times / day
Route: oral
Route: multiple
Dose: 27 mg, 1 times / day
Sources:
unhealthy, 50
n = 1
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 50
Sex: F
Population Size: 1
Sources:
Disc. AE: Encephalopathy, Peripheral neuropathy...
AEs leading to
discontinuation/dose reduction:
Encephalopathy
Peripheral neuropathy
Sources:
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.266
unhealthy, 51
n = 115
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 51
Sex: M+F
Population Size: 115
Sources: Page: p.266
Disc. AE: Distress gastrointestinal, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Distress gastrointestinal (0.9%)
Diarrhea (3.5%)
Rash (3.5%)
Mucosal ulceration (2.6%)
Leukopenia (0.9%)
Proteinuria (2.6%)
Sources: Page: p.266
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Hemoglobin decreased, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Hemoglobin decreased
Leukopenia
Agranulocytosis
Thrombocytopenia
Proteinuria
Hematuria
Pruritus
Rash
Stomatitis
Diarrhea
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 1.4%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.1310
unhealthy, 22-76
n = 72
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 22-76
Sex: M+F
Population Size: 72
Sources: Page: p.1310
Eosinophilia 1.4%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.1310
unhealthy, 22-76
n = 72
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 22-76
Sex: M+F
Population Size: 72
Sources: Page: p.1310
Leukopenia 1.4%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.1310
unhealthy, 22-76
n = 72
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 22-76
Sex: M+F
Population Size: 72
Sources: Page: p.1310
Stomatitis 1.4%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.1310
unhealthy, 22-76
n = 72
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 22-76
Sex: M+F
Population Size: 72
Sources: Page: p.1310
Bowel obstruction 1.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Dry mouth 1.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Glomerulonephritis 1.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Nausea 1.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Nephropathies 1.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Polyneuropathy 1.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Sweating 1.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Diarrhea 3%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Pruritus 6%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Exanthema 7.5%
Disc. AE
6 mg 1 times / day multiple, oral (total daily dose)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources: Page: p.254
unhealthy, 45-63
n = 67
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 45-63
Sex: M+F
Population Size: 67
Sources: Page: p.254
Encephalopathy Disc. AE
27 mg 1 times / day multiple, oral (total daily dose)
Overdose
Dose: 27 mg, 1 times / day
Route: oral
Route: multiple
Dose: 27 mg, 1 times / day
Sources:
unhealthy, 50
n = 1
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 50
Sex: F
Population Size: 1
Sources:
Peripheral neuropathy Disc. AE
27 mg 1 times / day multiple, oral (total daily dose)
Overdose
Dose: 27 mg, 1 times / day
Route: oral
Route: multiple
Dose: 27 mg, 1 times / day
Sources:
unhealthy, 50
n = 1
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 50
Sex: F
Population Size: 1
Sources:
Distress gastrointestinal 0.9%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.266
unhealthy, 51
n = 115
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 51
Sex: M+F
Population Size: 115
Sources: Page: p.266
Leukopenia 0.9%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.266
unhealthy, 51
n = 115
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 51
Sex: M+F
Population Size: 115
Sources: Page: p.266
Mucosal ulceration 2.6%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.266
unhealthy, 51
n = 115
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 51
Sex: M+F
Population Size: 115
Sources: Page: p.266
Proteinuria 2.6%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.266
unhealthy, 51
n = 115
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 51
Sex: M+F
Population Size: 115
Sources: Page: p.266
Diarrhea 3.5%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.266
unhealthy, 51
n = 115
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 51
Sex: M+F
Population Size: 115
Sources: Page: p.266
Rash 3.5%
Disc. AE
3 mg 2 times / day multiple, oral
Recommended
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources: Page: p.266
unhealthy, 51
n = 115
Health Status: unhealthy
Condition: Rheumatoid arthritis
Age Group: 51
Sex: M+F
Population Size: 115
Sources: Page: p.266
Agranulocytosis Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Diarrhea Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Hematuria Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Hemoglobin decreased Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Leukopenia Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Proteinuria Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Pruritus Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Rash Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Stomatitis Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
Thrombocytopenia Disc. AE
3 mg 3 times / day multiple, oral
Recommended
Dose: 3 mg, 3 times / day
Route: oral
Route: multiple
Dose: 3 mg, 3 times / day
Sources:
unhealthy
PubMed

PubMed

TitleDatePubMed
The subacute and chronic toxicity of SK&F 36914 and SK&F D-39162 in dogs.
1978 Aug
The subacute and chronic toxicity of SK&F 36914, SK&F D-39162 and gold sodium thiomalate in rats.
1978 Aug
[Multicenter double-blind comparison of auranofin and Tauredon].
1984
Proteinuria in gold-treated rheumatoid arthritis.
1984 Aug
Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.
1984 Jun
Neurotoxicity following a very high dose of oral gold (auranofin).
1984 Nov
An analysis of worldwide safety experience with auranofin.
1985 Aug
Long-term efficacy and safety of auranofin: a review of clinical experience.
1986
Auranofin versus penicillamine in rheumatoid arthritis. One-year results from a prospective clinical investigation.
1986
Nephrotic syndrome after oral gold.
1986 Aug
Hematuria in patients with rheumatoid arthritis receiving gold and D-penicillamine.
1987 Feb
[Gold-induced severe cholestatic jaundice in rheumatoid arthritis patient and effect of repeated steroid pulse therapy].
1992 Oct
Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes.
1999 Nov 26
Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase.
2000 Jun 1
HLA-DRB1*0301 and DQA1*0501 in RA.
2001 Jul
Nitritoid reactions: case reports, review, and recommendations for management.
2001 Oct
Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro.
2004 Jun
Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart.
2004 May-Jun
Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions.
2004 Oct
Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.
2006 Dec 1
A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]- to human serum albumin.
2006 Jul
Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
2006 Sep
Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity.
2007 Dec 15
Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system.
2008 Jun 1
The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation.
2008 Oct 30
Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift.
2009 Sep 15
The selenium-independent inherent pro-oxidant NADPH oxidase activity of mammalian thioredoxin reductase and its selenium-dependent direct peroxidase activities.
2010 Jul 9
Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA.
2011 Apr 14
The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity.
2011 Feb
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.
2011 Jun
Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors.
2011 Mar 15
Mitochondrial protection by the thioredoxin-2 and glutathione systems in an in vitro endothelial model of sepsis.
2011 May 15
Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1.
2011 Oct
Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism.
2011 Oct 1
Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells.
2013 Oct
Patents

Patents

Sample Use Guides

The usual adult dosage is 6 mg daily, given either as 3 mg twice daily or 6 mg once daily. Initiation of therapy at dosages exceeding 6 mg daily is not recommended because it is associated with an increased incidence of diarrhea. If response is inadequate after six months, an increase to 9 mg (3 mg three times daily) may be tolerated.
Route of Administration: Oral
Auranofin possesses potent antibacterial activity against all tested strains of S. aureus, including meticillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), with minimum inhibitory concentrations (MICs) ranging from 0.0625μg/mL to 0.125μg/mL.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:43:46 UTC 2021
Edited
by admin
on Fri Jun 25 20:43:46 UTC 2021
Record UNII
3H04W2810V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AURANOFIN
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
AURANOFIN [MART.]
Common Name English
AURANOFIN [INN]
Common Name English
GOLD, (2,3,4,6-TETRA-O-ACETYL-1-THIO-.BETA.-D-GLUCOPYRANOSATO-S)(TRIETHYLPHOSPHINE)-
Common Name English
SK&F-39162
Code English
RIDAURA
Brand Name English
AURANOFIN [HSDB]
Common Name English
NSC-321521
Code English
SK&F 39162
Code English
AURANOFIN [MI]
Common Name English
AURANOFIN [ORANGE BOOK]
Common Name English
SK-39162
Code English
(1-THIO-.BETA.-D-GLUCOPYRANOSATO)(TRIETHYLPHOSPHINE)GOLD 2,3,4,6-TETRAACETATE.
Common Name English
AURANOFIN [JAN]
Common Name English
AURANOFIN [USAN]
Common Name English
AURANOFIN [WHO-DD]
Common Name English
AURANOFIN [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC M01CB03
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
WHO-VATC QM01CB03
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
FDA ORPHAN DRUG 305210
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
NCI_THESAURUS C574
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
LIVERTOX 76
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
Code System Code Type Description
EPA CompTox
34031-32-8
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
ECHA (EC/EINECS)
251-801-9
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
ChEMBL
CHEMBL1366
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
EVMPD
SUB05610MIG
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
PUBCHEM
6918453
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
IUPHAR
6306
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
FDA UNII
3H04W2810V
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
CAS
34031-32-8
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
NCI_THESAURUS
C65242
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
MESH
D001310
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
RXCUI
1227
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB00995
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
DRUG CENTRAL
4122
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
MERCK INDEX
M2139
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY Merck Index
LACTMED
Auranofin
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
INN
3972
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
HSDB
7172
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
WIKIPEDIA
AURANOFIN
Created by admin on Fri Jun 25 20:43:46 UTC 2021 , Edited by admin on Fri Jun 25 20:43:46 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC